Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
298.90 USD   -0.98%
12/01Health Care Up on Drug Development, M&A Hopes -- Health Care Roundup
DJ
12/01There are two ways to look at Powell's speech
MS
12/01Transcript : Biogen Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Dec-01-2022 10:30 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Jumps After Alzheimer's Disease Treatment Meets Primary Endpoint in Phase 3 Trial, Analysts Reaction

09/28/2022 | 12:11pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.98% 298.9 Delayed Quote.24.58%
WELLS FARGO & COMPANY -1.98% 45.94 Delayed Quote.-4.25%
All news about BIOGEN INC.
12/01Health Care Up on Drug Development, M&A Hopes -- Health Care Roundup
DJ
12/01There are two ways to look at Powell's speech
MS
12/01Transcript : Biogen Inc. Presents at 5th Annual Evercore ISI HealthCONx Confe..
CI
12/01Atlantic Equities Adjusts Price Target on Biogen to $295 From $220, Maintains Neutral R..
MT
12/01UBS Adjusts Biogen Price Target to $338 From $319, Maintains Buy Rating
MT
12/01Analyst recommendations: Biogen, BAT, Hubbell, Liberty Global, P..
MS
11/30Stocks surge after Powell signals slower pace for rate hikes
RE
11/30Roche shutters most trials of Alzheimer's drug after failed trials
RE
11/30Stocks surge after Powell signals slower pace for rate hikes
RE
11/30Wall Street ends sharply higher after Powell comments
RE
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 067 M - -
Net income 2022 2 904 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 14,7x
Yield 2022 -
Capitalization 43 042 M 43 042 M -
EV / Sales 2022 4,30x
EV / Sales 2023 4,26x
Nbr of Employees 9 610
Free-Float 85,2%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 298,90 $
Average target price 319,38 $
Spread / Average Target 6,85%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP